All News
Filter News
Found 568 articles
-
Rocket Pharmaceuticals Presents Positive Data from LV Hematology and AAV Cardiovascular Gene Therapy Programs at the 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
5/19/2023
Rocket Pharmaceuticals, Inc. announced positive data from the Pyruvate Kinase Deficiency, Fanconi Anemia, Severe Leukocyte Adhesion Deficiency-I and Danon Disease clinical programs and PKP2-arrhythmogenic cardiomyopathy preclinical program presented at the 26th Annual Meeting of the American Society of Gene and Cell Therapy in Los Angeles, California.
-
Rocket Pharmaceuticals Announces FDA Clearance of IND for Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy (ACM)
5/9/2023
Rocket Pharmaceuticals, Inc. today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for the Company’s Investigational New Drug (IND) application for RP-A601.
-
Rocket Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Progress
5/4/2023
Rocket Pharmaceuticals, Inc. reported financial results for the quarter ending March 31, 2023, and updates from the Company’s key pipeline developments, business operations and upcoming milestones.
-
Rocket Pharmaceuticals to Participate in the Bank of America Securities 2023 Healthcare Conference
5/3/2023
Rocket Pharmaceuticals, Inc. announced that Gaurav Shah, M.D., Chief Executive Officer, is scheduled to participate in a fireside chat at the Bank of America Securities 2023 Healthcare Conference in Las Vegas, Nevada on Wednesday, May 10, 2023 at 4:20 p.m. PT.
-
REGENXBIO Reports First Quarter 2023 Financial Results and Recent Operational Highlights
5/3/2023
REGENXBIO Inc. (Nasdaq: RGNX) today announced financial results for the first quarter ended March 31, 2023, and recent operational highlights.
-
Amgen Reports First Quarter 2023 Financial Results
4/27/2023
Amgen announced financial results for the first quarter of 2023.
-
Ascidian Therapeutics Announces Three Key Development Team Appointments as It Advances Its Lead Program Toward the Clinic
4/11/2023
Ascidian Therapeutics announced today three new appointments to its growing development team as the company advances its lead program into the clinic.
-
Rocket Pharmaceuticals to Participate in Upcoming April 2023 Investor Conferences
4/11/2023
Rocket Pharmaceuticals, Inc. announced that Company management will participate in the 22nd Annual Needham Virtual Healthcare Conference and Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit.
-
Rocket Pharmaceuticals Announces Leadership Expansion to Support Company on Evolution Towards Commercial Stage
4/4/2023
Rocket Pharmaceuticals, Inc., a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, announced expansion of its leadership team to support its growing and industry-leading pipeline of AAV and LV gene therapy assets and evolution towards commercial stage.
-
Rocket Pharmaceuticals to Participate in the 43rd Annual Cowen Health Care Conference
3/1/2023
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) today announced that Gaurav Shah, M.D., Chief Executive Officer, is scheduled to participate in the Genetic Medicines Corporate Panel at the 43rd Annual Cowen Health Care Conference taking place in Boston, MA on Monday, March 6, 2023 at 10:30 a.m. ET.
-
REGENXBIO Reports Fourth Quarter 2022 and Full-Year 2022 Financial Results and Recent Operational Highlights
2/28/2023
REGENXBIO Inc. (Nasdaq: RGNX) today announced financial results for the fourth quarter and full-year ended December 31, 2022, and recent operational highlights.
-
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial and Operational Results
2/27/2023
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and operational results for the fourth quarter and year ended December 31, 2022.
-
Rocket Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
2/9/2023
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) today announced that Gaurav Shah, M.D., Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the SVB Securities Global Biopharma Conference on Thursday, February 16, at 2:20 p.m. ET.
-
Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A501 Gene Therapy for Danon Disease
2/7/2023
Rocket Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to RP-A501.
-
AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS
1/31/2023
Amgen (NASDAQ: AMGN) today announced financial results for the fourth quarter and full year 2022 versus comparable periods in 2021.
-
Rocket Pharmaceuticals Expands Cardiac Gene Therapy Portfolio with Addition of RP-A601 for PKP2-ACM and Announces Positive Updated Phase 1 Data for RP-A501 in Danon Disease
1/9/2023
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) today announces the addition of RP-A601 to Rocket’s cardiac gene therapy portfolio as well as anticipated highlights for the year ahead across the Company’s world-class pipeline of lentiviral and AAV gene therapy programs targeting rare hematologic and cardiovascular diseases.
-
Rocket Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference
1/3/2023
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) today announces that Gaurav Shah, M.D., Chief Executive Officer, is scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023, at 2:15 p.m. PT.
-
Rocket Pharmaceuticals Provides Update on Anticipated Registration Path for RP-A501 in Danon Disease Following End-of-Phase 1 FDA Meeting
12/22/2022
Rocket Pharmaceuticals, Inc. today announces updates from the Company's end-of-Phase 1 meeting with the U.S. Food and Drug Administration (FDA) regarding RP-A501, the Company's investigational adeno-associated virus (AAV)-based gene therapy for Danon Disease.
-
Edgewise Therapeutics Appoints Marc Semigran, M.D., As Chief Development Officer
12/20/2022
Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for individuals with devastating muscle disorders, announced today the appointment of Marc Semigran, M.D., as Chief Development Officer.
-
Rocket Pharmaceuticals Presents Positive Clinical Data from Fanconi Anemia, Pyruvate Kinase Deficiency and Severe Leukocyte Adhesion Deficiency-I Programs at the 64th American Society of Hematology (ASH) Annual Meeting
12/12/2022
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announces positive clinical data from its lentiviral (LV)-based gene therapy programs at the 64th American Society of Hematology (ASH) Annual Meeting.